EUVIMEDEUVIMED entdecken
Open Access

Glucagon Prescribing and Costs Among U.S. Adults With Diabetes, 2011–2021

Joseph R Herges iD, Rodolfo J Galindo iD, Joshua J Neumiller iD, Herbert C Heien, Guillermo E Umpierrez iD, Rozalina G McCoy iD

Diabetes Care · 01.03.2023 · 46 (3) · 620-627

DOI: 10.2337/dc22-1564 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Diabetes Care, online erschienen am 11.01.2023. Verfasst von Joseph R Herges und 5 weiteren Autor:innen. Beteiligte Einrichtung: 1Pharmacy Services, Mayo Clinic, Rochester, MN. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 1, Hypoglycemia. Die Arbeit wurde bisher 28-mal zitiert (Crossref) und nennt 32 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIDDK NIH HHS, National Institute of Diabetes and Digestive and Kidney Diseases.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

OBJECTIVE To characterize contemporary trends in glucagon fill rates and expenditures in a nationwide cohort of adults with diabetes overall and by key demographic and clinical characteristics. RESEARCH DESIGN AND METHODS In this retrospective cohort study, we examined 1) glucagon fill rates per 1,000 person-years and 2) patient out-of-pocket and health plan costs per filled glucagon dose among adults with diabetes included in OptumLabs Data Warehouse between 1 January 2011 and 31 March 2021. RESULTS The study population comprised 2,814,464 adults with diabetes with a mean age of 62.8 (SD 13.2) years. The overall glucagon fill rate decreased from 2.91 to 2.28 per 1,000 person-years (−22%) over the study period. In groups at high risk for severe hypoglycemia, glucagon fill rates increased from 22.46 to 36.76 per 1,000 person-years (64%) among patients with type 1 diabetes, 11.64 to 16.63 per 1,000 person-years (43%) among those treated with short-acting insulin, and 16.08 to 20.12 per 1,000 person-years (25%) among those with a history of severe hypoglycemia. White patients, women, individuals with high income, and commercially insured patients had higher glucagon fill rates compared with minority patients, males, individuals with low income, and Medicare Advantage patients, respectively. Total cost per dosing unit increased from $157.97 to $275.32 (74%) among commercial insurance beneficiaries and from $150.37 to $293.57 (95%) among Medicare Advantage beneficiaries. CONCLUSIONS Glucagon fill rates are concerningly low and declined between 2011 and 2021 but increased in appropriate subgroups with type 1 diabetes, using short-acting insulin, or with a history of severe hypoglycemia. Fill rates were disproportionately low among minority patients and individuals with low income.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Diabetes Mellitus, Type 1HypoglycemiaAgedMaleHumansAdultFemaleUnited StatesMiddle AgedGlucagonRetrospective StudiesMedicareInsulin, Short-Acting

Substanzen

GlucagonInsulin, Short-Acting

Autor:innen und Institutionen

  • 1Pharmacy Services, Mayo Clinic, Rochester, MN.
  • 2Division of Endocrinology and Metabolism, Emory University, Atlanta, GA.
  • 3Department of Pharmacotherapy, Washington State University, Spokane, WA.
  • 4Division of Health Care Delivery Research, Mayo Clinic Robert D. and Patricia E. Kern Center for the Science of Health Care Delivery, Rochester, MN.
  • 5Division of Community Internal Medicine, Geriatrics, and Palliative Care, Mayo Clinic, Rochester, MN.
  • 6OptumLabs, Eden Prairie, MN.

ORCID-Profile: Joseph R Herges, Rodolfo J Galindo, Joshua J Neumiller, Guillermo E Umpierrez, Rozalina G McCoy

Förderung

  • NIDDK NIH HHS
  • National Institute of Diabetes and Digestive and Kidney Diseases

Zitieren

APA

Herges, J. R., Galindo, R. J., Neumiller, J. J., Heien, H. C., Umpierrez, G. E., & McCoy, R. G. (2023). Glucagon Prescribing and Costs Among U.S. Adults With Diabetes, 2011–2021. Diabetes Care, 46(3), 620-627. https://doi.org/10.2337/dc22-1564

Vancouver

Herges JR, Galindo RJ, Neumiller JJ, Heien HC, Umpierrez GE, McCoy RG. Glucagon Prescribing and Costs Among U.S. Adults With Diabetes, 2011–2021. Diabetes Care. 2023;46(3):620-627. doi:10.2337/dc22-1564

BibTeX
@article{Herges2023,
  author = {Herges, Joseph R and Galindo, Rodolfo J and Neumiller, Joshua J and Heien, Herbert C and Umpierrez, Guillermo E and McCoy, Rozalina G},
  title = {Glucagon Prescribing and Costs Among U.S. Adults With Diabetes, 2011–2021},
  journal = {Diabetes Care},
  year = {2023},
  volume = {46},
  number = {3},
  pages = {620--627},
  doi = {10.2337/dc22-1564}
}
Kostenlos starten →